New Stock News | Zhejiang Jingxin Pharmaceutical (002020.SZ) submits listing application to Hong Kong Stock Exchange.

According to the disclosure by the Hong Kong Stock Exchange on February 11, Zhejiang Jingxin Pharmaceutical Co., Ltd. (referred to as Zhejiang Jingxin Pharmaceutical) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CITIC SEC as its exclusive sponsor. The prospectus shows that Zhejiang Jingxin Pharmaceutical (002020.SZ) is a pharmaceutical group driven by innovation, with a strategic focus on two core disease areas: central nervous system diseases; and cardiovascular and cerebrovascular diseases. The company's business model combines the commercialization of existing products with the continuous advancement of its product pipeline. The current product portfolio includes pharmaceuticals (including generics, innovative drugs, traditional Chinese medicine, and biologics); active pharmaceutical ingredients; and medical devices.